Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | KEYNOTE-426 – Pembrolizumab plus axitinib versus sunitinib for mRCC

Thomas Powles • 15 May 2020
ASCO 2020
Genitourinary Cancer Kidney Cancer Antibodies Axitinib Pembrolizumab Sunitinib
KEYNOTE-426

Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, outlines KEYNOTE-426 (NCT02853331), a study that evaluated the efficacy and safety of pembrolizumab in combination with axitinib versus sunitinib monotherapy as a first-line treatment for participants with advanced/metastatic renal cell carcinoma (mRCC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Thomas Powles

2:04
Unmet educational needs in GU cancers
Thomas Powles • 16 Feb 2023
2:37
Key unmet needs in kidney cancer
Thomas Powles • 16 Feb 2023
1:44
Highlights in renal cell carcinoma from ASCO GU 2023 and what to look out for in the future
Thomas Powles • 23 Feb 2023
4:01
COSMIC-313: cabo + nivo + ipi in 1L advanced RCC of IMDC intermediate or poor risk
Thomas Powles • 16 Feb 2023

Related Videos

0:57
Real-world outcomes of 177Lu-PSMA-617 in mCRPC
Hannah McManus • 8 Apr 2024
0:38
Emerging combinatory immunotherapies show promise for mCRPC
Hannah McManus • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals